FDA Entry Point vs Registrar Corp: OTC Drug and SPL Submission Support

Introduction

OTC drug manufacturers comparing FDA Entry Point and Registrar Corp are not choosing between a filing service and an advice-only service. Both vendors publicly offer Structured Product Labeling file preparation and FDA submission. The decision is who will own the complete path from labeler code and XML construction through Electronic Submissions Gateway Next Generation submission, validation-error correction, accepted acknowledgements, and recurring listing maintenance.

FDA requires establishment registration, labeler code requests, and drug listings to use Structured Product Labeling in XML format. Commercial or in-house SPL submissions, other than those sent through FDA Direct or Xforms, travel through the Electronic Submissions Gateway Next Generation, commonly called ESG NextGen. FDA drug registration and listing instructions

FDA Entry Point prepares and submits OTC SPL files on the client’s behalf, including Drug Facts content, establishment registration SPLs, drug listing SPLs, labeler code submissions, amendments, and label-change resubmissions. Registrar Corp also performs the technical filing work, including labeler code requests, SPL creation, schema validation, submission through FDA’s system, and listing monitoring. The practical comparison therefore turns on the operating scope surrounding the upload, not vendor size. FDA Entry Point SPL services Registrar Corp drug product listing services

Key takeaways

• Both vendors perform SPL submissions. Registrar Corp creates the listing SPL and submits it through FDA’s system; FDA Entry Point prepares and submits SPL files on the client’s behalf.
• FDA Entry Point is the stronger fit when the same provider must handle U.S. Agent coverage and the filings. Its published scope connects U.S. Agent service, establishment registration, labeler code and NDC work, SPL submission, label-change updates, and annual renewal tracking. FDA Entry Point drug and pharmaceutical services
• Registrar Corp is the stronger fit when a regulatory team prioritizes a portal-centered listing workflow. Its drug listing service includes schema validation, submission monitoring, a real-time dashboard, document storage, and a full audit trail. Registrar Corp drug product listing services
• The filing does not end when the XML is uploaded. Buyers need the submission acknowledgements, resolution of validation failures, the accepted SPL version, and a calendar covering June and December listing reviews plus the October 1 to December 31 registration and certification period. FDA electronic drug registration and listing system

Side-by-side comparison

Table basis: FDA Entry Point SPL services, FDA Entry Point drug and pharmaceutical services, Registrar Corp drug product listing services, and Registrar Corp drug compliance services.

When FDA Entry Point is the stronger choice

FDA Entry Point is the stronger choice when a foreign OTC drug manufacturer wants the filing work performed on its behalf and wants the same provider to remain responsible for U.S. Agent communications, annual establishment renewal, NDC listing maintenance, and later label updates. Its published SPL scope is executional: it prepares and files the XML rather than stopping at instructions or a compliance memo. FDA Entry Point SPL services

The actual SPL/XML path FDA Entry Point performs

1. Establish submission access and authorization. The electronic submitter needs ESG NextGen access. A manufacturer submitting for itself registers its own account and completes any test submission required for the relevant FDA center and submission type. FDA also allows consultants and U.S. Agents to submit for clients through an agency account with a client authorization letter. FDA ESG NextGen consultant account process
2. Obtain or update the labeler code. A labeler code must exist before the drug listing is submitted. FDA Entry Point prepares labeler code SPL submissions as part of its published scope.
3. Prepare the establishment registration SPL. The file includes establishment identity, DUNS information, operations, official contact, and, for a foreign establishment, U.S. Agent and importer information. Foreign establishments must register before their drugs are offered for import. FDA establishment registration instructions
4. Build and validate the drug listing SPL/XML. The file incorporates the proposed NDC, proprietary and established names, dosage form, route, active and inactive ingredients, manufacturing establishments, current Drug Facts content, and package-label images. Initial listings for products present at initial establishment registration are due within three calendar days after registration. FDA drug listing instructions
5. Submit through ESG NextGen. FDA Entry Point coordinates the electronic transmission of the establishment registration SPL, labeler code SPL, and drug listing SPL rather than handing the client an XML file and leaving the upload to its regulatory manager.
6. Review acknowledgements and resolve validation failures. ESG NextGen issues acknowledgements covering upload, routing, and, where applicable, the receiving center’s response. A failed file must be corrected and resubmitted until the applicable acceptance record is received. FDA ESG NextGen submission acknowledgements
7. Maintain the accepted record. Label and product changes require a new SPL version with the original set ID, a new document or root ID, a later effective date, an incremented version number, and revised data or labeling.
8. Complete recurring updates. Drug listings are reviewed in June and December, unchanged listings require annual certification, and establishment registration is reviewed and renewed from October 1 through December 31.

What FDA Entry Point performs and what remains with the manufacturer

FDA Entry Point performs SPL preparation, electronic submission, amendments, resubmissions, version tracking, establishment registration, NDC listing support, and annual update coordination. The manufacturer remains responsible for supplying accurate legal-entity data, formulation and ingredient information, manufacturing-site details, current commercial labels, and authorization to submit. The manufacturer also approves the accuracy of the regulatory record before filing.

Substantive label compliance review is a separate published service from basic SPL submission. Buyers should not treat XML conversion as proof that the underlying Drug Facts content, claims, formulation, or OTC monograph position is compliant. That distinction matters because a technically valid SPL can still reproduce an inaccurate source label.

When Registrar Corp is the stronger choice

Registrar Corp is the stronger choice when the regulatory team wants a portal-centered listing workflow with formal document storage, listing-status visibility, schema validation, renewal monitoring, and a clearly described audit trail. Its public process is not limited to consulting: Registrar Corp requests the labeler code, creates the listing SPL, submits through FDA’s system, validates the file, and monitors the listing. Registrar Corp drug product listing services

• Choose Registrar Corp if dashboard visibility is part of the control model. Its public service includes a real-time dashboard for listing status and renewals.
• Choose it if document storage and audit retrieval are procurement requirements. Registrar Corp publicly includes document backup and a full audit trail within an ISO 27001-certified system.
• Choose it if OTC monograph validation must sit next to the filing workflow. Its broader drug service scope includes monograph validation, labeler code assignment, drug label assessment, and SPL file management. Registrar Corp drug compliance services
• Choose it if the organization already has separate U.S. Agent and regulatory communication controls. The value case is strongest when the immediate need is a managed listing workflow rather than one provider owning both agent duties and filing continuity.

What usually determines the decision

The decisive question is who owns each submission event after the initial listing. OTC drug records can require an updated drug listing SPL, an establishment registration SPL, a labeler code SPL, or more than one filing. A vendor comparison is incomplete unless it identifies the trigger, the file to submit, the deadline, and who resolves a rejected submission.

SPL and registration update triggers

Regulatory basis: FDA drug registration and listing instructions, FDA guidance on listing and updating a drug, and 21 CFR Part 207.

What to require in the vendor deliverables

• The final submitted SPL/XML file and every later accepted version.
• The ESG NextGen Core ID and applicable acknowledgement records.
• A record of validation errors, corrections, and resubmissions.
• The accepted establishment registration, labeler code, and drug listing records.
• A current NDC and product-status inventory showing active, discontinued, and reintroduced products.
• A calendar covering June and December listing reviews, annual no-change certification, and October 1 to December 31 establishment renewal.
• Clear ownership and transfer procedures for account access, source XML, labels, acknowledgements, and correspondence if the vendor relationship ends.

Why buyers switch in this category

OTC drug manufacturers usually switch after discovering that “SPL support” meant file authoring but not submission ownership. The client received an XML file but was still expected to obtain ESG access, perform the upload, interpret acknowledgements, resolve validation failures, and remember every update cycle.

The most consequential breakdowns are mechanical: the submitted label differs from the commercial label, a new NDC is never listed, an old manufacturing establishment remains attached to the product, a discontinuation is not reported, or an upload receipt is mistaken for final acceptance. FDA publishes detailed validation rules because successful transmission and an accepted regulatory record are not the same event. FDA SPL validation rules

A clean handoff requires more than a confirmation email. The outgoing record should include the latest accepted XML, set IDs, document IDs, version history, ESG acknowledgements, validation correspondence, active NDC inventory, annual certification status, and the next registration deadline.

Frequently asked questions

Does FDA Entry Point submit OTC drug SPL/XML files, or does it only advise the manufacturer?

FDA Entry Point prepares and submits OTC drug SPL/XML files on the manufacturer’s behalf. Its published scope includes Drug Facts SPL preparation, establishment registration SPLs, drug listing SPLs, NDC labeler code submissions, ESG coordination, amendments, resubmissions, version tracking, and annual update coordination. The manufacturer supplies and approves the underlying company, product, ingredient, establishment, and labeling information. FDA Entry Point SPL services

Does a foreign OTC drug manufacturer need its own ESG NextGen account?

Not necessarily. A foreign manufacturer that submits directly needs ESG NextGen access and must complete any test submission required for the relevant center and submission type. FDA also permits a consultant, CRO, or U.S. Agent to submit under its agency account after receiving an authorization letter from the client. The engagement should identify who is the electronic submitter and who retains the acknowledgements, Core IDs, accepted files, and account records. FDA ESG NextGen account process for consultants and U.S. Agents

What should a foreign drug manufacturer update after an OTC label change?

The manufacturer should update the drug listing SPL when the commercial label or submitted package image changes. The new version retains the original set ID, receives a new document or root ID, uses a later effective date and version number, and incorporates the revised Drug Facts content, product data, or label images. FDA instructs registrants to update listings as soon as possible and no later than the following June or December. FDA instructions for updating a drug listing

What are the recurring FDA deadlines after the first SPL submission?

Drug listing information must be reviewed in June and December, with new products, material changes, resumptions, and discontinuations reported through the applicable listing update. Listings not otherwise updated during the year can be covered by an annual no-change certification from October 1 through December 31. Establishment registration is also reviewed and renewed from October 1 through December 31, while specified establishment and contact changes are due within 30 calendar days. 21 CFR Part 207

Which vendor is better for generic or OTC drug companies that care about audit trail and responsiveness?

FDA Entry Point is the stronger fit when responsiveness, U.S. Agent coverage, and submission execution need to sit with one accountable team. It publishes a 24-business-hour response standard and connects agent duties to SPL, NDC, registration, and renewal work. Registrar Corp is the stronger fit when the buyer prioritizes a dashboard, formal document backup, listing-status monitoring, and a publicly specified audit trail. Both perform the filing, so the decision is the surrounding control model rather than technical capability alone. FDA Entry Point drug services Registrar Corp drug listing services

Is pricing transparency still a differentiator in this comparison?

Yes. FDA Entry Point publishes separate starting prices for U.S. Agent service, establishment registration, product listing, SPL submission, and label review. That separation helps a regulatory manager distinguish XML filing from substantive label review and annual agent coverage. Registrar Corp’s cited drug service pages explain the workflow and deliverables but do not display equivalent current prices, so its total cost requires a quote.

References

• FDA Entry Point Structured Product Labeling services
• FDA Entry Point drug and pharmaceutical U.S. Agent services
• FDA Entry Point drug registration renewals
• Registrar Corp drug product listing services
• Registrar Corp drug compliance services
• FDA drug registration and listing instructions
• FDA instructions for registering a drug establishment
• FDA instructions for listing and updating a drug
• FDA Electronic Submissions Gateway Next Generation
• FDA ESG NextGen submission acknowledgements
• Electronic Code of Federal Regulations, 21 CFR Part 207